XML 45 R35.htm IDEA: XBRL DOCUMENT v3.5.0.2
Acquisition (Details) - USD ($)
$ / shares in Units, shares in Thousands, $ in Thousands
3 Months Ended
Nov. 05, 2015
Jun. 24, 2015
May 28, 2016
May 30, 2015
Feb. 27, 2016
Apr. 02, 2015
Preliminary purchase price allocation            
Goodwill     $ 1,713,475   $ 1,713,475  
Unaudited pro forma combined financial data            
Bridge loan commitment fees incurred with the Acquisition by both the Company and EnvisionRx     15,375      
Net revenues     8,184,181 $ 6,647,561    
Less pre-acquisition intercompany revenue       (79,899)    
Pro forma combined revenues     8,184,181 7,939,139    
Income before income taxes     (10,897) 31,277    
Net (loss) income     (4,588) 18,836    
Incremental interest expense on the 6.125% Notes issued on April 2, 2015       (9,617)    
Incremental amortization resulting from fair value adjustments of the identifiable intangible assets       (10,988)    
Transaction costs incurred by both the Company and EnvisionRx       19,110    
Income tax benefit (expense) relating to pro forma adjustments       (11,302)    
Pro forma net (loss) income     $ (4,588) $ 35,372    
Basic and diluted (loss) income per share (in dollars per share)     $ 0.00 $ 0.03    
Pharmacy Services            
Preliminary purchase price allocation            
Goodwill   $ 1,637,351        
Amount of goodwill deductible for tax purpose   $ 1,360,156        
6.125% senior notes due 2023            
Acquisitions            
Principal amount of debt     $ 1,800,000   $ 1,800,000  
Debt instrument, stated interest rate (as a percent)     6.125%   6.125%  
EnvisionRx            
Acquisitions            
Ownership interest (as a percent)   100.00%        
Stock consideration (in shares)   27,754        
Share price   $ 8.68        
Preliminary purchase price            
Cash consideration $ 116,500 $ 1,882,211        
Stock consideration   240,907        
Total   2,123,118        
Preliminary purchase price allocation            
Cash and cash equivalents   103,834        
Accounts receivable   896,473        
Inventories   7,276        
Prepaid expenses and other current assets   13,386        
Total current assets   1,020,969        
Property and equipment   13,196        
Intangible assets(1)   646,600        
Goodwill   1,637,351        
Other assets   7,219        
Total assets acquired   3,325,335        
Accounts payable   491,672        
Reinsurance funds held   381,225        
Other current liabilities(2)   216,937        
Total current liabilities   1,089,834        
Other long term liabilities(3)   112,383        
Total liabilities assumed   1,202,217        
Net assets acquired   2,123,118        
Amount due under the terms of agreement   116,500        
Acquisition costs     $ 6 $ 17,459    
EnvisionRx | Trademarks            
Preliminary purchase price allocation            
Estimated Fair Value of indefinite lived intangible assets   33,500        
EnvisionRx | Customer relationships            
Preliminary purchase price allocation            
Estimated Fair Value of Finite lived intangible assets   $ 465,000        
Estimated Useful Life   17 years        
EnvisionRx | CMS license            
Preliminary purchase price allocation            
Estimated Fair Value of Finite lived intangible assets   $ 57,500        
Estimated Useful Life   25 years        
EnvisionRx | Claims adjudication and other developed software            
Preliminary purchase price allocation            
Estimated Fair Value of Finite lived intangible assets   $ 59,000        
Estimated Useful Life   7 years        
EnvisionRx | Trademarks            
Preliminary purchase price allocation            
Estimated Fair Value of Finite lived intangible assets   $ 20,100        
Estimated Useful Life   10 years        
EnvisionRx | Backlog            
Preliminary purchase price allocation            
Estimated Fair Value of Finite lived intangible assets   $ 11,500        
Estimated Useful Life   3 years        
EnvisionRx | 6.125% senior notes due 2023            
Acquisitions            
Principal amount of debt           $ 1,800,000
Debt instrument, stated interest rate (as a percent)           6.125%
EnvisionRx            
Unaudited pro forma combined financial data            
Net revenues       1,371,477    
Income before income taxes       11,238    
Interest expense incurred by EnvisionRx       $ 18,095